Does Liraglutide Mimic The Vascular Benefits Of Gastric Bypass Surgery?Friday, March 27, 2015
On the last day of the 8th Annual Obesity Symposium here in Norderstedt, Germany, Marco Bueter from the University of Zurich presented a fascinating series of studies (just published in Circulation), demonstrating the “weight-independent” benefits of gastric bypass surgery on endothelial function (using an animal model).
Besides showing that 8 days after bypass surgery rats with diet-induced obesity had higher plasma levels of bile acids and GLP-1, that were associated with improved endothelium-dependent relaxation, not seen in sham-operated weight matched controls, but also that these effects could be prevented by blocking GLP-1 receptors with exendin 9-39.
In contrast, similar effects to those seen on vascular function in bypass rats were seen in sham-operated rats treated for 8 days with the GLP-1 analogue, liraglutide, or as the authors describe it,
“liraglutide restored NO bioavailability and improved endothelium-dependent relaxations and HDL endothelium-protective properties, mimicking the effects of RYGB”
Together these studies suggest that GLP-1 may well play an important causal role in the improved vascular function seen in patients undergoing gastric bypass surgery.
These findings are all the more interesting as liraglutide has now been approved for obesity treatment in the USA, Canada and Europe.
While these data are certainly not enough to describe liraglutide as “surgery in a pen”, they are indeed promising in terms of potential benefits of this treatment that may well be weight independent.
All the more reason to anticipate the outcome of the ongoing LEADER trial, which is currently evaluating the effect of liraglutide treatment on cardiovascular outcomes in patients with type 2 diabetes.
Disclaimer: I have served as a paid consultant and speaker for Novo Nordisk, the maker of liraglutide.
Sunday, March 29, 2015
Excellent post. It is really exciting to see what surgery has taught us about weight management, and how we can apply this to the medical options. Impact will not as great as surgery, but what a great option for patients who do not qualify for surgery.
Sunday, April 5, 2015
Vielen Dank für diesen Artikel.
Das “Arzneitelegramm” sieht die Anwendung von Liraglutid ja kritisch und rät eindeutig NICHT zur Verordnung.
Ich bin selbst Internistin und hausärztlich tätig, mit einer großen Anzahl von sowohl adipösen Patienten als auch Typ-II-Diabetikern. Eine neue Option zur Behandlung von adipösen Patienten wäre ein Lichtstreif am Himmel.
Gibt es in nächster Zeit die Möglichkeit Sie Dr.Sharma in Deutschland auf einem Kongress etc. zu hören? Über eine positive Antwort würde ich mich wirklich freuen.
Herzlichen Dank und viele Grüße aus dem kalt-sonnigen Ahrtal in Deutschland